Single Protein Encapsulated SN38 for Tumor-Targeting Treatment.

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• SN38, a potent camptothecin analog, faces clinical limitations due to poor water solubility.
• Existing SN38 prodrugs like irinotecan exhibit low conversion rates to active SN38, impacting efficacy.
• Novel drug delivery systems are needed to improve SN38's therapeutic index for cancer treatment.

Approach:

• Developed a single protein encapsulation (SPE) technology using human serum albumin (HSA) to formulate SN38.
• Created two SN38 complexes, SPESN38-5 and SPESN38-8, utilizing the SPE platform.
• Conducted comprehensive pharmacological evaluations, including maximum tolerated dose, pharmacokinetics, and in vivo antitumor efficacy in mouse models.

Key Points:

• SPESN38 complexes form stable aqueous solutions, enhancing SN38's solubility.
• SPESN38-5 demonstrated favorable pharmacokinetics and antitumor activity against colorectal cancer xenografts, outperforming irinotecan with lower toxicity.
• SPESN38-8 showed significant efficacy in inhibiting soft tissue sarcoma growth with minimal toxicity, unlike doxorubicin.

Conclusions:

• SPESN38 complexes offer a viable solution for delivering SN38 effectively.
• These novel formulations exhibit improved pharmacokinetic profiles, reduced systemic toxicity, and superior antitumor efficacy compared to current standards of care.
• SPE technology holds promise for developing next-generation cancer therapeutics based on SN38.